Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 17, 2019 07:00 ET | Source: Amarantus Bioscience Holdings, Inc.

MANF Therapeutics Receives Notices of Allowance Covering MANF Use as Treatment for Parkinson's in Europe and Diabetes in Japan

New York, NY, Jan. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MANF Therapeutics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) in pre-clinical development...
January 15, 2019 07:00 ET | Source: Amarantus Bioscience Holdings, Inc.

MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDNF as a Treatment for Glaucoma, Macular Degeneration and Retinitis Pigmentosa

New York, NY, Jan. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MANF Therapeutics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) in pre-clinical development...
January 07, 2019 08:00 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Provides 2019 Roadmap

NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the "Company," or AMBS), a US-based, JLABS-alumnus biotechnology holding company...
November 28, 2018 07:55 ET | Source: Amarantus Bioscience Holdings, Inc.

Coeptis Pharma Enters into Agreement to Acquire Elto Pharma

NEW YORK and WEXFORD, Pa., Nov. 28, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Coeptis Pharmaceuticals, Inc., a diversified commercial biopharmaceutical company, today announced that it has entered...
July 20, 2018 08:17 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Provides Corporate Update

NEW YORK, July 20, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company," or AMBS), a US-based JLABS-alumnus biotechnology holding company...
July 09, 2018 08:00 ET | Source: Amarantus Bioscience Holdings, Inc.

MANF Therapeutics Announces Positive MANF Pre-Clinical Data inAlpha-Synuclein Model of Parkinson's DiseasePublished in Peer-Reviewed Journal Experimental Neurobiology

NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- MANF Therapeutics, Inc., a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) in pre-clinical development...
June 11, 2018 07:00 ET | Source: Amarantus Bioscience Holdings, Inc.

MANF Therapeutics Announces Independent Publication of Positive Data for MANF in Traumatic Brain Injury Animal Model

NEW YORK, June 11, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--MANF Therapeutics, Inc., a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) in pre-clinical development...
June 07, 2018 09:08 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Provides Update on Elto Pharma Capital Formation Plan

NEW YORK, June 07, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire – Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company," or AMBS), a US-based, JLABS-alumnus biotechnology holding...
June 05, 2018 08:11 ET | Source: Amarantus Bioscience Holdings, Inc.

MANF Therapeutics Announces Publication of Positive Data for MANF in Stroke Animal Model in AAAS Journal Science Advances

NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- MANF Therapeutics, Inc., a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) in pre-clinical development...
May 30, 2018 08:00 ET | Source: Amarantus Bioscience Holdings, Inc.

Amarantus Exercises Exclusive Option with Leipzig University for Alzheimer's Blood Diagnostic "LymPro Test 2.0"

Scope of exercised Exclusive Option Agreement expanded to include negotiations for IP rights to additional key markers collected in German clinical study, including CSF-tau NEW YORK, May 30, 2018 ...